Hans van Houte - 10 Feb 2026 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role
Chief Financial Officer
Signature
/s/ Daniel Burbach, as Attorney-in-Fact for Hans van Houte
Issuer symbol
NRIX
Transactions as of
10 Feb 2026
Net transactions value
$0
Form type
4
Filing time
10 Feb 2026, 18:09:29 UTC
Previous filing
30 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
van Houte Hans Chief Financial Officer C/O NURIX THERAPEUTICS, INC., 1600 SIERRA POINT PKWY, BRISBANE /s/ Daniel Burbach, as Attorney-in-Fact for Hans van Houte 10 Feb 2026 0001817217

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRIX Employee Stock Option (right to buy) Award $0 +93,750 $0.000000 93,750 10 Feb 2026 Common Stock 93,750 $16.45 Direct F1
transaction NRIX Restricted Stock Units Award $0 +42,875 $0.000000 42,875 10 Feb 2026 Common Stock 42,875 $0.000000 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 1/36 of the total shares monthly beginning March 10, 2026, until the option is fully vested on February 9, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F3 The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
F4 RSUs do not expire; they either vest or are canceled prior to the vest date.